QC
MLYS icon

Quadrature Capital’s Mineralys Therapeutics MLYS Stock Holding History

Quadrature Capital’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,987
Closed -$162K – 1314
2025
Q2 		$162K Sell
11,987
-61,021
-84% -$884K ﹤0.01% 845
2025
Q1 		$1.16M Buy
+73,008
New +$840K 0.03% 399

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quadrature Capital's MLYS Position: Q3 2025 in Review

Quadrature Capital sold out of Mineralys Therapeutics (MLYS) in Q3 2025, closing a stake of 11,987 shares — an estimated $162K sold.

Quadrature Capital first reported a position in MLYS in Q1 2025 and held it in 2 quarters. The position peaked at $1.16M in Q1 2025. 193 funds tracked by Wall St. Rank hold MLYS as of Q3 2025.

  • Quadrature Capital reported no remaining Mineralys Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quadrature Capital sold 11,987 Mineralys Therapeutics shares in Q3 2025, an estimated $162K.
  • Quadrature Capital first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 2 quarters.
  • Quadrature Capital's Mineralys Therapeutics position peaked at $1.16M in Q1 2025.
  • 193 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2025.

Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.